Ticker Details
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
IPO Date:	July 24, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$138.91B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$2.16 | 1.80%
Avg Daily Range (30 D):	$8.47 | 1.70%
Avg Daily Range (90 D):	$6.65 | 1.41%

Institutional Daily Volume
Avg Daily Volume:	1.58M
Avg Daily Volume (30 D):	.93M
Avg Daily Volume (90 D):	1M

Trade Size
Avg Trade Size (Sh.):	87
Avg Trade Size (Sh.) (30 D):	24
Avg Trade Size (Sh.) (90 D):	25

Institutional Trades
Total Institutional Trades:	30,992
Avg Institutional Trade:	$9.49M
Avg Institutional Trade (30 D):	$57.14M
Avg Institutional Trade (90 D):	$50.51M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$35.52M
Avg Closing Trade (30 D):	$152.36M
Avg Closing Trade (90 D):	$152.19M
Avg Closing Volume:	150.91K

News

Aug 22, 2026 @ 11:05 AM Which Biotech ETF Is a Better Buy: Concentrated Be... Source: Seena Hassouna

Aug 21, 2026 @ 11:02 AM IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?... Source: Andy Gould

Aug 20, 2026 @ 7:30 PM Vertex Pharmaceuticals' Rally Has a New Engine -- ... Source: Prosper Junior Bakiny

Aug 19, 2026 @ 11:15 AM Invesco Nasdaq Biotech vs. Invesco Pharma: How Do ... Source: Erin Kennedy

Aug 5, 2026 @ 7:02 PM State Street XLV vs VanEck BBH: Which Healthcare E... Source: Brendan Coffey

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$17.33	$4.34	$4.06
Diluted EPS	$17.17	$4.31	$4.02
Revenue	$12.59B	$3.33B	$2.99B
Gross Profit	$10.82B	$2.84B	$2.59B
Net Income / Loss	$4.41B	$1.1B	$1.03B
Operating Income / Loss	$4.78B	$1.25B	$1.14B
Cost of Revenue	$1.76B	$489.2M	$392.8M
Net Cash Flow	$1.17B	$649.2M	$417.1M
PE Ratio

Splits
Aug 24, 2000	2:1